Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease

References

• EblyEMParhadIMHoganDBFungTSPrevalence and types of dementia in the very old: results from the Canadian Study of Health and AgingNeurology199444159316007936280
   PubMed Web of Science ®Google Scholar
• CummingsJLAlzheimer’s diseaseN Engl J Med2004351566715229308
   PubMed Web of Science ®Google Scholar
• GotzJIttnerLMSchonrockNCappaiRAn update on the toxicity of Abeta in Alzheimer’s diseaseNeuropsychiatr Dis Treat200841033104219337449
   PubMedGoogle Scholar
• ArmstrongRAPlaques and tangles and the pathogenesis of Alzheimer’s diseaseFolia Neuropathol20064411116565925
   PubMed Web of Science ®Google Scholar
• WalshDMKlyubinIFadeevaJVRowanMJSelkoeDJAmyloid-beta oligomers: their production, toxicity and therapeutic inhibitionBiochem Soc Trans20023055255712196135
   PubMed Web of Science ®Google Scholar
• MackenzieIRSenile plaques do not progressively accumulate with normal agingActa Neuropathol1994875205258059605
   PubMed Web of Science ®Google Scholar
• OlneyJWWozniakDFFarberNBExcitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategiesArch Neurol199754123412409341569
   PubMedGoogle Scholar
• MolinuevoJLLladoARamiLMemantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementiasAm J Alzheimers Dis Other Demen200520778515844753
   PubMedGoogle Scholar
• DanyszWParsonsCGThe NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidenceInt J Geriatr Psychiatry200318S23S3212973747
   PubMed Web of Science ®Google Scholar
• WhetsellWOJShapiraNANeuroexcitation, excitotoxicity and human neurological diseaseLab Invest1993683723878479146
   PubMed Web of Science ®Google Scholar
• HyndMRScottHLDoddPRGlutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s diseaseNeurochem Int20044558359515234100
   PubMed Web of Science ®Google Scholar
• RammesGDanyszWParsonsCGPharmacodynamics of memantine: an updateCurr Neuropharmacol20086557819305788
   PubMed Web of Science ®Google Scholar
• ChohanMOIqbalKFrom tau to toxicity: emerging roles of NMDA receptor in Alzheimer’s diseaseJ Alzheimers Dis200610818716988485
   PubMed Web of Science ®Google Scholar
• WaltonHSDoddPRGlutamate-glutamine cycling in Alzheimer’s diseaseNeurochem Int2007501052106617141374
   PubMed Web of Science ®Google Scholar
• WenkGLMcGann-GramlingKHauss-WegrzyniakBAttenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acidJ Neurochem20048948449315056291
   PubMed Web of Science ®Google Scholar
• RosiSRamirez-AmayaVHauss-WegrzyniakBWenkGLChronic brain inflammation leads to a decline in hippocampal NMDA-R1 receptorsJ Neuroinflammation200411215285803
   PubMed Web of Science ®Google Scholar
• RosiSVazdarjanovaARamirez-AmayaVWorleyPFBarnesCAWenkGLMemantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the ratNeuroscience20061421303131516989956
   PubMed Web of Science ®Google Scholar
• ParsonsCGDanyszWQuackGMemantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist – a review of preclinical dataNeuropharmacology19993873576710465680
   PubMed Web of Science ®Google Scholar
• PericlouAVenturaDRaoNAbramowitzWPharmacokinetic study of memantine in healthy and renally impaired subjectsClin Pharmacol Ther20067913414316413248
   PubMed Web of Science ®Google Scholar
• PericlouAPVenturaDShermanTRaoNAbramowitzWTLack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezilAnn Pharmacother2004381389139415266045
   PubMed Web of Science ®Google Scholar
• WinbladBPoritisNMemantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine)Int J Geriatr Psychiatry19991413514610885864
   PubMed Web of Science ®Google Scholar
• ReisbergBDoodyRStofflerASchmittFFerrisSMobiusHJMemantine in moderate-to-severe Alzheimer’s diseaseN Engl J Med20033481333134112672860
   PubMed Web of Science ®Google Scholar
• TariotPNFarlowMRGrossbergGTGrahamSMMcDonaldSGergelIMemantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trialJAMA200429131732414734594
   PubMed Web of Science ®Google Scholar
• van DyckCHTariotPNMeyersBMalca ResnickEA 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer diseaseAlzheimer Dis Assoc Disord20072113614317545739
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders3rd editionrevised (DSM-III-R).Washington, DCAPA1987
   Google Scholar
• ReisbergBFerrisSHde LeonMJCrookTThe Global Deterioration Scale for assessment of primary degenerative dementiaAm J Psychiatry1982139113611397114305
   PubMed Web of Science ®Google Scholar
• FermLBehavioural activities in demented geriatric patients Study based on evaluations made by nursing staff members and on patients’ scores on a simple psychometric testGerontol Clin (Basel)1974161851944435361
   PubMedGoogle Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders4th edition(DSM-IV).Washington, DCAPA1994
   Google Scholar
• SclanSGReisbergBFunctional assessment staging (FAST) in Alzheimer’s disease: reliability, validity, and ordinalityInt Psychogeriatr19924Suppl 155691504288
   PubMedGoogle Scholar
• GalaskoDBennettDSanoMAn inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative StudyAlzheimer Dis Assoc Disord199711Suppl 2S33S399236950
   PubMed Web of Science ®Google Scholar
• SchneiderLSOlinJTDoodyRSValidity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer’s Disease Cooperative StudyAlzheimer Dis Assoc Disord199711Suppl 2S22S329236949
   PubMed Web of Science ®Google Scholar
• GalaskoDR SFJinSDetailed assessment of cognition and activities of daily living in moderate to severe Alzheimer’s disease. [abstract]Neurobiol Aging200021S168
   Google Scholar
• PanissetMRoudierMSaxtonJBollerFSevere impairment battery. A neuropsychological test for severely demented patientsArch Neurol19945141458274108
   PubMed Web of Science ®Google Scholar
• SchmittFAAshfordWErnestoCThe severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer’s disease. The Alzheimer’s Disease Cooperative StudyAlzheimer Dis Assoc Disord199711Suppl 2S51S569236953
   PubMed Web of Science ®Google Scholar
• CummingsJLMegaMGrayKRosenberg-ThompsonSCarusiDAGornbeinJThe Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementiaNeurology199444230823147991117
   PubMed Web of Science ®Google Scholar
• ReisbergBDoodyRStofflerASchmittFFerrisSMobiusHJA 24-week open-label extension study of memantine in moderate to severe Alzheimer diseaseArch Neurol200663495416401736
   PubMed Web of Science ®Google Scholar
• KerteszAMemantine in moderate to severe Alzheimer’s diseaseCurr Neurol Neurosci Rep2003348548614565902
   PubMedGoogle Scholar
• BleichSWiltfangJKornhuberJMemantine in moderate-to-severe Alzheimer’s diseaseN Engl J Med2003349609610author reply 609–610.12904528
   PubMed Web of Science ®Google Scholar
• WimoAWinbladBStofflerAWirthYMobiusHJResource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s diseasePharmacoeconomics20032132734012627986
   PubMed Web of Science ®Google Scholar
• RiveBVercellettoMDamierFDCochranJFrancoisCMemantine enhances autonomy in moderate to severe Alzheimer’s diseaseInt J Geriatr Psychiatry20041945846415156547
   PubMed Web of Science ®Google Scholar
• van DyckCHSchmittFAOlinJTA responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezilAm J Geriatr Psychiatry20061442843716670247
   PubMed Web of Science ®Google Scholar
• SchmittFAvan DyckCHWichemsCHOlinJTCognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysisAlzheimer Dis Assoc Disord20062025526217132970
   PubMed Web of Science ®Google Scholar
• CummingsJLSchneiderETariotPNGrahamSMBehavioral effects of memantine in Alzheimer disease patients receiving donepezil treatmentNeurology200667576316832078
   PubMed Web of Science ®Google Scholar
• FeldmanHHSchmittFAOlinJTActivities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatmentAlzheimer Dis Assoc Disord20062026326817132971
   PubMed Web of Science ®Google Scholar
• RosenWGTerryRDFuldPAKatzmanRPeckAPathological verification of ischemic score in differentiation of dementiasAnn Neurol198074864887396427
   PubMed Web of Science ®Google Scholar
• AtriAShaughnessyLWLocascioJJGrowdonJHLong-term course and effectiveness of combination therapy in Alzheimer diseaseAlzheimer Dis Assoc Disord20082220922118580597
   PubMed Web of Science ®Google Scholar
• BlessedGTomlinsonBERothMThe association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjectsBr J Psychiatry19681147978115662937
   PubMed Web of Science ®Google Scholar
• WSThe record of independent daily living: an informant completed measure of activities of daily living and behavior in elderly patients with cognitive impairmentAmerican Journal Alzheimer Care198613539
   Google Scholar
• FarlowMRGrahamSMAlvaGMemantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trialsDrug Saf20083157758518558791
   PubMed Web of Science ®Google Scholar
• JonesRWBayerAInglisFBarkerAPhulRSafety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer’s diseaseInt J Geriatr Psychiatry20072225826217243195
   PubMed Web of Science ®Google Scholar
• WaldemarGHyvarinenMJosiassenMKKornerALehtoHWetterbergPTolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer’s diseaseInt J Geriatr Psychiatry20082397998118229874
   PubMed Web of Science ®Google Scholar
• GauthierSLoftHCummingsJImprovement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysisInt J Geriatr Psychiatry20082353754518058838
   PubMed Web of Science ®Google Scholar
• WilcockGKBallardCGCooperJALoftHMemantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studiesJ Clin Psychiatry20086934134818294023
   PubMed Web of Science ®Google Scholar
• MaidmentIDFoxCGBoustaniMRodriguezJBrownRCKatonaCLEfficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysisAnn Pharmacother200842323818056833
   PubMed Web of Science ®Google Scholar
• CummingsJLMackellJKauferDBehavioral effects of current Alzheimer’s disease treatments: a descriptive reviewAlzheimers Dement20084496018631950
   PubMed Web of Science ®Google Scholar
• GrossbergGTPejovicVMillerMLGrahamSMMemantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer’s diseaseDement Geriatr Cogn Disord20092716417219194105
   PubMed Web of Science ®Google Scholar
• PeskindERPotkinSGPomaraNMemantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trialAm J Geriatr Psychiatry20061470471516861375
   PubMed Web of Science ®Google Scholar
• PorsteinssonAPGGMintzerJOlinJTMemantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trialCurr Alzheimer Res20085838918288936
   PubMed Web of Science ®Google Scholar
• BakchineSLoftHMemantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month studyJ Alzheimers Dis20071147147917656827
   PubMed Web of Science ®Google Scholar
• VidalJSLacombeJMDartiguesJFEvaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care databaseNeuroepidemiology20083119320018815451
   PubMed Web of Science ®Google Scholar
• FarlowMRCummingsJLEffective pharmacologic management of Alzheimer’s diseaseAm J Med200712038839717466645
   PubMed Web of Science ®Google Scholar
• DantoineTAuriacombeSSarazinMBeckerHPereJJBourdeixIRivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer’s disease who failed to benefit from previous cholinesterase inhibitor treatmentInt J Clin Pract20066011011816409439
   PubMed Web of Science ®Google Scholar
• HsiungGYFeldmanHHPharmacological treatment in moderate-to-severe Alzheimer’s diseaseExpert Opin Pharmacother200892575258218803446
   PubMed Web of Science ®Google Scholar
• StoleePRockwoodKFoxRAStreinerDLThe use of goal attainment scaling in a geriatric care settingJ Am Geriatr Soc1992405745781587973
   PubMed Web of Science ®Google Scholar
• RockwoodKStoleePHowardKMalleryLUse of Goal Attainment Scaling to measure treatment effects in an anti-dementia drug trialNeuroepidemiology1996153303388930946
   PubMed Web of Science ®Google Scholar
• JacovaCSchulzerMMoneyJCross-sectional validation of a new instrument for the measurement of treatment response: the Clinical Meaningfulness in Alzheimer Disease Treatment (CLIMAT) scaleAlzheimers Dement20095184
   Google Scholar
• JacovaCSchulzerMMoneyJSocial impact in the measurement of clinically meaningful change: Findings from the cross-sectional validation of the Clinical Meaningfulness in Alzheimer Disease Treatment (CLIMAT) scaleAlzheimers Dement20095188
   Google Scholar
• GagnonMRiveBHuxMGuilhaumeCCost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in CanadaCan J Psychiatry20075251952617955915
   PubMed Web of Science ®Google Scholar
• AntonanzasFRiveBBadenasJMGomez-LusSGuilhaumeCCost-effectiveness of memantine in community-based Alzheimer’s disease patients: An adaptation in SpainEur J Health Econ2006713714416670912
   PubMedGoogle Scholar
• JonesRWMcCronePGuilhaumeCCost effectiveness of memantine in Alzheimer’s disease: an analysis based on a probabilistic Markov model from a UK perspectiveDrugs Aging20042160762015260515
   PubMed Web of Science ®Google Scholar
• FrancoisCSintonenHSulkavaRRiveBCost effectiveness of memantine in moderately severe to severe Alzheimer’s disease: a markov model in FinlandClin Drug Investig200424373384
   PubMed Web of Science ®Google Scholar
• JonssonLCost-effectiveness of memantine for moderate to severe Alzheimer’s disease in SwedenAm J Geriatr Pharmacother20053778616129384
   PubMedGoogle Scholar
• GeldmacherDSCost-effectiveness of drug therapies for Alzheimer’s disease: A brief reviewNeuropsychiatr Dis Treat2008454955518830441
   PubMedGoogle Scholar